bluebird bio (MUN:BLE) - Cotización, noticias y análisis

Resumen de acción BLE

bluebird bio, Inc, empresa de biotecnología, investiga, desarrolla y comercializa terapias génicas para enfermedades genéticas graves.

Acerca de la empresa

BLE fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 40.56%

Los beneficios han crecido un 18.9% al año en los últimos 5 años

Análisis de riesgos

Acciones altamente ilíquidas

Los accionistas han sido diluidos sustancialmente en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de bluebird bio, Inc.

Heidelberg Pharma

XTRA:HPHA

€139.8m

Medigene

XTRA:MDG1

€37.8m

Formycon

XTRA:FYB

€792.1m

Biotest

XTRA:BIO3

€1.4b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for bluebird bio
Historical stock prices
Current Share Price	US$0.92
52 Week High	US$4.75
52 Week Low	US$0.86
Beta	0.80
1 Month Change	-18.25%
3 Month Change	n/a
1 Year Change	-76.55%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-94.41%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	BLE	DE Biotechs	Mercado DE
7D	7.5%	0.4%	1.8%
1Y	-76.6%	-21.9%	4.2%

Rentabilidad vs. Industria: BLE obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del -24.4%.

Rentabilidad vs. Mercado: BLE obtuvo unos resultados inferiores a los del mercado German, que fue del 1.3% el año pasado.

Volatilidad de los precios

Is BLE's price volatile compared to industry and market?
BLE volatility
BLE Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.4%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: El precio de las acciones de BLE ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de BLE en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1992	323	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc, empresa de biotecnología, investiga, desarrolla y comercializa terapias génicas para enfermedades genéticas graves. Sus productos candidatos para enfermedades genéticas graves incluyen ZYNTEGLO (betibeglogene autotemcel) para el tratamiento de la ß-talasemia dependiente de transfusión; lovotibeglogene autotemcel para el tratamiento de la anemia falciforme (ECF); y SKYSONA (elivaldogene autotemcel) para tratar la adrenoleucodistrofia cerebral. Los programas de desarrollo clínico de la empresa incluyen HGB-205, HGB-206 y HGB-210 para evaluar la seguridad y eficacia de lovo-cel en el tratamiento de pacientes con ECF; y HGB-204, HGB-205, HGB-207 y HGB-212 para evaluar la seguridad y eficacia de beti-cel en el tratamiento de pacientes con ß-talasemia.

Resumen de fundamentos de bluebird bio, Inc.

¿Cómo se comparan los beneficios e ingresos de bluebird bio con su capitalización de mercado?
Estadísticas fundamentales de BLE
Capitalización bursátil	€179.19m
Beneficios(TTM)	-€84.76m
Ingresos (TTM)	€20.20m

9.0x

Ratio precio-ventas (PS)

-2.1x

Ratio precio-beneficio (PE)

¿Está BLE sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BLE
Ingresos	US$21.73m
Coste de los ingresos	US$255.71m
Beneficio bruto	-US$233.98m
Otros gastos	-US$142.81m
Beneficios	-US$91.17m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

May 09, 2024

Beneficios por acción (BPA)	-0.47
Margen bruto	-1,076.97%
Margen de beneficio neto	-419.62%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado BLE a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BLE

Recompensas

Análisis de riesgos

Competidores de bluebird bio, Inc.

XTRA:HPHA

€139.8m

XTRA:MDG1

€37.8m

XTRA:FYB

€792.1m

XTRA:BIO3

€1.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Recent updates

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 41% undervalued after recent price drop

Bluebird Bio, Inc. Announces FDA Approval of LYFGENIA™? (Lovo-Ccel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Now 24% undervalued

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Insider selling

President recently sold €54k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold €78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold €94k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

CEO & Director recently sold €65k worth of stock

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022

bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy

New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels

Bluebird Bio, Inc. Announces FDA Priority Review of Biologics License Application for Beti-Cel Gene Therapy for Patients with ß-Thalassemia Who Require Regular Red Blood Cell Transfusions

Third quarter 2021 earnings released: US$3.16 loss per share (vs US$2.94 loss in 3Q 2020)